Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事述职报告（武滨）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2022 Annual Work Report" for Ruikang Pharmaceutical Group Co., Ltd. It is a detailed report by an independent director summarizing their activities, opinions, attendance, investigations, and contributions during the year 2022. The content focuses on the director's duties, opinions on board decisions, attendance at meetings, and efforts to protect shareholder rights. It does not contain financial statements or audit results, nor is it an announcement or certification. It is a management-related report focusing on board and director activities rather than a financial report or regulatory filing. Therefore, the document best fits the category of Board/Management Information (MANG). The document length is 2269 characters, which is consistent with a detailed report but not a full annual report or audit report. Confidence is high given the clear focus on director activities and opinions.
2023-04-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 27th meeting of the 4th Board of Directors of Ruikang Pharmaceutical Group Co., Ltd. It includes approval of the 2022 Annual Report and its summary, the 2022 General Manager's Work Report, the 2022 Board Work Report, the 2022 Financial Final Accounts Report and 2023 Financial Budget Report, internal control reports, profit distribution plan, and the 2023 Q1 report. It also discusses nominations for the 5th Board of Directors and independent directors, and other corporate governance matters. The document contains substantive financial data such as revenue, profit, and net profit figures for 2022, and it is not merely an announcement of a report publication but includes actual financial results and management decisions. The document is not a full Annual Report (10-K) but rather a Board meeting resolution announcement that includes approval of various reports and proposals to be submitted to the shareholders' meeting. It also includes detailed information about board member nominations and governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG), as it primarily announces board meeting resolutions including management and governance decisions, rather than being the full annual report or a simple announcement of report publication.
2023-04-28 Chinese
营业收入扣除情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is an audit-related report issued by Tianyuanquan Certified Public Accountants LLP concerning the 2022 fiscal year financial statements of Ruikang Pharmaceutical Group Co., Ltd. It specifically provides a special audit opinion on the company's 2022 operating revenue deduction situation, referencing the audited financial statements and compliance with Shenzhen Stock Exchange guidelines. The document includes detailed audit responsibilities, management responsibilities, and the auditor's special verification opinion. It is not the full annual report but a standalone audit verification report related to a specific aspect of the financial statements. Therefore, it fits the category of an Audit Report / Information (AR). The document length (5560 characters) and content confirm it is a substantive audit report, not merely an announcement or certification. FY 2022
2023-04-28 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of 瑞康医药集团股份有限公司, dated April 2023. It contains detailed financial data for the year 2022, including revenue, net profit, cash flow, and segment business descriptions. It also includes information on shareholders and corporate structure. The length is 8571 characters, which is substantial and contains actual financial statements and analysis, not just an announcement or a certification. The content matches the characteristics of an Annual Report (10-K) or its summary. Given it is explicitly called an "Annual Report Summary" and contains comprehensive financial and business information for the fiscal year, the appropriate classification is Annual Report (10-K). FY 2022
2023-04-28 Chinese
瑞康医药集团股份有限公司独立董事提名人声明-孙考祥
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. The document length is 3834 characters, which is relatively short and does not contain financial data or report publication language. Therefore, it is best classified as Board/Management Information (MANG).
2023-04-28 Chinese
关于公司提供担保进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from 瑞康医药集团股份有限公司 regarding the progress of guarantees provided by the company and its subsidiaries. It details the scope, amounts, and types of guarantees, including specific financial institutions and guarantee amounts. The document includes no financial statements or detailed financial performance data, but rather focuses on the status and overview of guarantees, which is a form of capital or financing update. The document length is short (1544 characters), and it is not a report publication announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP).
2023-04-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.